Internal medicine

Melanoma

Immunotherapy

Cancer

Oncology

Nivolumab

Ipilimumab

Metastatic melanoma

Cancer research

Medicine

The Lancet Oncology

Nivolumab combined with ipilimumab and nivolumab monotherapy are active in melanoma brain metastases. A high proportion of patients achieved an intracranial response with the combination. Thus, nivolumab combined with ipilimumab should be considered as a first-line therapy for patients with asymptomatic untreated brain metastases.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study